Acquired: Describes a condition that is developed later in life. It may be unknown why aTTP is developed.
Thrombotic: Refers to the small blood clots that form inside blood vessels.
Thrombocytopenic: Means having a low platelet count.
Purpura: Red- or purple-colored spots on the skin that do not go away when pressure is applied. It may look like a bruise.
Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare, life-threatening blood disorder. You may hear your doctor or some people refer to it as TTP. This is a general term. The 2 main types of TTP are inherited and acquired; however, 95% of all TTP cases are acquired.
One of the components in your blood that helps your platelets Platelets: A small cell found in the blood and involved in clotting. stick together is called von Willebrand factor (vWF) von Willebrand factor: One of the components in your blood that helps your platelets stick together. . Platelets are small cells found in the blood and are involved in clotting. Their main job is to form blood clots when bleeding happens. Platelets stick together to seal a cut or injury. This stops bleeding.
In people with aTTP, the body’s immune system makes proteins called autoantibodies that stop ADAMTS13 from cutting up vWF.
These large molecules of vWF attract platelets. This forms blood clots even when there is no bleeding. These clots:
It may not be known why someone develops aTTP, but the following could be triggers:
Blood flow without aTTP
Blood clot risk in aTTP
Everyone’s experience with aTTP is different. You may have had some of the following symptoms. These can be signs of aTTP and could be a warning of having another aTTP episode. This is called a recurrence Recurrence: Any aTTP episode that follows the first aTTP event. .
Blood clot–related symptoms
Do not take CABLIVI if you’ve had an allergic reaction to caplacizumab-yhdp or to any of the ingredients in CABLIVI.
Tell your doctor if you have a medical condition including if you have a bleeding disorder. Tell your doctor about any medicines you take.
Talk to your doctor before scheduling any surgery, medical or dental procedure.
CABLIVI can cause severe bleeding. In clinical studies, severe bleeding adverse reactions of nosebleed, bleeding from the gums, bleeding in the stomach or intestines, and bleeding from the uterus were each reported in 1% of subjects. Contact your doctor immediately if excessive bleeding or bruising occur.
You may have a higher risk of bleeding if you have a bleeding disorder (i.e. hemophilia) or if you take other medicines that increase your risk of bleeding such as anti-coagulants.
CABLIVI should be stopped for 7 days before surgery or any medical or dental procedure. Talk to your doctor before you stop taking CABLIVI.
The most common side effects include nosebleed, headache and bleeding gums.
Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of CABLIVI. Call your doctor for medical advice about side effects.
CABLIVI (caplacizumab-yhdp) is a prescription medicine used for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.